CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| NRG-GY001 | NRG | A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent; Clear Cell Carcinoma of the Ovary; Fallopian Tube; or Peritoneum | Adult CIRB - Late Phase Emphasis | Completed |
| S1609 | SWOG | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
| NRG-GY031 | NRG | A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| GOG-0201 | GOG | Treatment of Patients with Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemoradiation VERSUS Primary Chemoradiation | Adult CIRB - Late Phase Emphasis | Completed |
| EA8192 | ECOG-ACRIN | A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | Adult CIRB - Late Phase Emphasis | Available to Open |
| SWOG-9007 | SWOG | Cytogenetic Studies in Leukemia Patients | Adult CIRB - Late Phase Emphasis | Completed |
| CALGB-30801 | CALGB | A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| E5508 | ECOG | Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
| E3F05 | ECOG | Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas | Adult CIRB - Late Phase Emphasis | Available to Open |
| N0723 | NCCTG | MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib | Adult CIRB - Late Phase Emphasis | Completed |